Terms: = Ovarian cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
131 results:
1. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
2. Small-molecule inhibitor HI-TOPK-032 improves NK-92MI cell infiltration into ovarian tumours.
Deng M; Yang R; Sun Q; Zhang J; Miao J
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):629-642. PubMed ID: 38501576
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria R; Knisely A; Vining D; Kopetz S; Overman MJ; Javle M; Antonoff MB; Tzeng CD; Wolff RA; Pant S; Lito K; Rangel K; Fellman B; Yuan Y; Lu KH; Sakellariou-Thompson D; Haymaker CL; Forget MA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309721
[TBL] [Abstract] [Full Text] [Related]
4. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME; Santegoets SJ; Welters MJP; de Bruin L; Visser M; van der Minne CE; de Kok PM; Loof NM; Boekestijn S; Roozen I; Westra IM; Meij P; Van der Burg SH; Kroep JR
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949617
[TBL] [Abstract] [Full Text] [Related]
5. ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Herzog TJ; Hays JL; Barlin JN; Buscema J; Cloven NG; Kong LR; Tyagi NK; Lanneau GS; Long BJ; Marsh RL; Seward SM; Starks DC; Welch S; Moore KN; Konstantinopoulos PA; Gilbert L; Monk BJ; O'Malley DM; Chen X; Dalal R; Coleman RL; Sehouli J
Future Oncol; 2023 Jul; 19(23):1577-1591. PubMed ID: 37334673
[TBL] [Abstract] [Full Text] [Related]
6. Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer.
Kumar P; Ranmale S; Mehta S; Tongaonkar H; Patel V; Singh AK; Mania-Pramanik J
J Ovarian Res; 2023 Jun; 16(1):114. PubMed ID: 37322531
[TBL] [Abstract] [Full Text] [Related]
7. Effects of leptin on the viability of human ovarian cancer cells and changes in cytokine expression levels.
Dincer F; Atmaca H; Akman L; Oktay LM; Karaca B; Terek MC
PeerJ; 2023; 11():e15246. PubMed ID: 37155466
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of the Occurrence of Predicative Factors of Chronic Fatigue in Female Patients with cancer of the Reproductive Organs with Respect to Stage of treatment.
Kłysiak M; Wieder-Huszla S; Branecka-Woźniak D; Karakiewicz-Krawczyk K; Napieracz-Trzosek I; Owsianowska J; Jurczak A; Cymbaluk-Płoska A
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36834426
[TBL] [Abstract] [Full Text] [Related]
9. Generation and Functional Characterization of PLAP CAR-T Cells against Cervical cancer Cells.
Yekehfallah V; Pahlavanneshan S; Sayadmanesh A; Momtahan Z; Ma B; Basiri M
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139135
[TBL] [Abstract] [Full Text] [Related]
10. Herpesvirus entry mediator regulates the transduction of Tregs via STAT5/Foxp3 signaling pathway in ovarian cancer cells.
Shan Y; Zhang B; Chen L; Zhang H; Jiang C; You Q; Li Y; Han H; Zhu J
Anticancer Drugs; 2023 Jan; 34(1):73-80. PubMed ID: 35946515
[TBL] [Abstract] [Full Text] [Related]
11. Proapoptotic Effect of Icariin on Human ovarian cancer Cells via the NF-[Formula: see text]B/PI3K-AKT Signaling Pathway: A Network Pharmacology-Directed Experimental Investigation.
Gao J; Fu Y; Song L; Long M; Zhang Y; Qin J; Liu H
Am J Chin Med; 2022; 50(2):589-619. PubMed ID: 35114909
[TBL] [Abstract] [Full Text] [Related]
12. TIL expansion with high dose il-2 or low dose il-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones.
Kongkaew T; Thaiwong R; Tudsamran S; Sae-Jung T; Sengprasert P; Vasuratna A; Suppipat K; Reantragoon R
J Immunol Methods; 2022 Apr; 503():113229. PubMed ID: 35101548
[TBL] [Abstract] [Full Text] [Related]
13. ovarian cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.
Tonetti CR; de Souza-Araújo CN; Yoshida A; da Silva RF; Alves PCM; Mazzola TN; Derchain S; Fernandes LGR; Guimarães F
Cells; 2021 Jul; 10(7):. PubMed ID: 34359872
[TBL] [Abstract] [Full Text] [Related]
14. Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
Santos J; Heiniö C; Quixabeira D; Zafar S; Clubb J; Pakola S; Cervera-Carrascon V; Havunen R; Kanerva A; Hemminki A
Cells; 2021 Apr; 10(5):. PubMed ID: 33922052
[TBL] [Abstract] [Full Text] [Related]
15. Study on the regulatory mechanism and experimental verification of icariin for the treatment of ovarian cancer based on network pharmacology.
Wang S; Gao J; Li Q; Ming W; Fu Y; Song L; Qin J
J Ethnopharmacol; 2020 Nov; 262():113189. PubMed ID: 32736044
[TBL] [Abstract] [Full Text] [Related]
16. Cytokine-induced Killer T Cells Enhance the Cytotoxicity Against Carboplatin-resistant ovarian cancer Cells.
Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
Anticancer Res; 2020 Jul; 40(7):3865-3872. PubMed ID: 32620626
[TBL] [Abstract] [Full Text] [Related]
17. Serum cytokines and CXCR2: potential tumour markers in ovarian neoplasms.
Micheli DC; Jammal MP; Martins-Filho A; Côrtes JRXM; Souza CN; Nomelini RS; Murta EFC; Tavares-Murta BM
Biomarkers; 2020 Sep; 25(6):474-482. PubMed ID: 32544350
[TBL] [Abstract] [Full Text] [Related]
18. MiR-140-3p inhibits natural killer cytotoxicity to human ovarian cancer via targeting MAPK1.
Wang J; Zhu M; Zhou X; Wang T; Xi Y; Jing Z; Xi W
J Biosci; 2020; 45():. PubMed ID: 32385217
[TBL] [Abstract] [Full Text] [Related]
19. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
[TBL] [Abstract] [Full Text] [Related]
20. Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors.
Qiao G; Wang X; Zhou X; Morse MA; Wu J; Wang S; Song Y; Jiang N; Zhao Y; Zhou L; Zhao J; Di Y; Zhu L; Hobeika A; Ren J; Lyerly HK
Int J Hyperthermia; 2019 Nov; 36(sup1):74-82. PubMed ID: 31795830
[No Abstract] [Full Text] [Related]
[Next]
